W. Jeffrey Petty

3.5k total citations
110 papers, 2.6k citations indexed

About

W. Jeffrey Petty is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, W. Jeffrey Petty has authored 110 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 64 papers in Oncology, 62 papers in Pulmonary and Respiratory Medicine and 27 papers in Molecular Biology. Recurrent topics in W. Jeffrey Petty's work include Lung Cancer Research Studies (38 papers), Lung Cancer Treatments and Mutations (36 papers) and Lung Cancer Diagnosis and Treatment (29 papers). W. Jeffrey Petty is often cited by papers focused on Lung Cancer Research Studies (38 papers), Lung Cancer Treatments and Mutations (36 papers) and Lung Cancer Diagnosis and Treatment (29 papers). W. Jeffrey Petty collaborates with scholars based in United States, United Kingdom and Canada. W. Jeffrey Petty's co-authors include Ethan Dmitrovsky, Antonius A. Miller, Luis Paz‐Ares, Konstantin H. Dragnev, A. William Blackstock, Jimmy Ruiz, Dawen Zhao, Amyn A. Habib, William Crowe and Kathryn E. Weaver and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

W. Jeffrey Petty

103 papers receiving 2.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
W. Jeffrey Petty United States 28 1.2k 1.0k 886 325 212 110 2.6k
Arta M. Monjazeb United States 34 1.6k 1.3× 966 0.9× 550 0.6× 1.3k 3.9× 192 0.9× 123 3.2k
Paul Cozzi Australia 31 1.0k 0.9× 911 0.9× 1.3k 1.5× 265 0.8× 350 1.7× 67 2.9k
William Proctor Harris United States 24 1.4k 1.2× 948 0.9× 829 0.9× 297 0.9× 271 1.3× 88 3.1k
Amanda J. Redig United States 22 1.5k 1.2× 1.5k 1.4× 1.2k 1.3× 222 0.7× 143 0.7× 39 3.1k
Kostas Syrigos Greece 30 1.6k 1.4× 1.1k 1.1× 1.0k 1.2× 211 0.6× 210 1.0× 114 3.3k
Amit A. Lugade United States 21 1.4k 1.1× 494 0.5× 626 0.7× 1.3k 4.1× 163 0.8× 42 2.7k
Xiaodong Zhu China 25 692 0.6× 520 0.5× 610 0.7× 144 0.4× 298 1.4× 164 2.2k
Adnan Ghafoor United States 2 1.5k 1.2× 907 0.9× 891 1.0× 174 0.5× 282 1.3× 3 3.2k
Urban Emmenegger Canada 32 1.5k 1.3× 923 0.9× 1.3k 1.5× 463 1.4× 142 0.7× 150 3.4k
Tokujiro Yano Japan 35 1.4k 1.2× 1.8k 1.7× 804 0.9× 352 1.1× 161 0.8× 143 3.3k

Countries citing papers authored by W. Jeffrey Petty

Since Specialization
Citations

This map shows the geographic impact of W. Jeffrey Petty's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by W. Jeffrey Petty with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites W. Jeffrey Petty more than expected).

Fields of papers citing papers by W. Jeffrey Petty

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by W. Jeffrey Petty. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by W. Jeffrey Petty. The network helps show where W. Jeffrey Petty may publish in the future.

Co-authorship network of co-authors of W. Jeffrey Petty

This figure shows the co-authorship network connecting the top 25 collaborators of W. Jeffrey Petty. A scholar is included among the top collaborators of W. Jeffrey Petty based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with W. Jeffrey Petty. W. Jeffrey Petty is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ganti, Apar Kishor, Briant Fruth, Andreas Rimner, et al.. (2024). Quality of life outcomes in patients participating in the CALGB 30610 trial (CALGB 70702): Alliance. Cancer. 131(1). e35663–e35663. 1 indexed citations
2.
D’Agostino, Ralph B., Steven E. Glynn, M. D. Smith, et al.. (2024). Genomic Signature for Leptomeningeal Progression in Brain Metastasis Patients Using Liquid Biopsy-Acquired Comprehensive Genomic Profiling. International Journal of Radiation Oncology*Biology*Physics. 120(2). S190–S191.
3.
McLouth, Laurie E., Jennifer Gabbard, Beverly J. Levine, et al.. (2023). Prognostic Awareness, Palliative Care Use, and Barriers to Palliative Care in Patients Undergoing Immunotherapy or Chemo-Immunotherapy for Metastatic Lung Cancer. Journal of Palliative Medicine. 26(6). 831–836. 10 indexed citations
4.
Bellinger, Christina, Kristie L. Foley, Emily V. Dressler, et al.. (2022). Organizational Characteristics and Smoking Cessation Support in Community-Based Lung Cancer Screening Programs. Journal of the American College of Radiology. 19(4). 529–533. 5 indexed citations
5.
Hughes, Ryan T., James J. Urbanic, Hollins Clark, et al.. (2021). Long-Term Outcomes From a Phase 2 Trial of Radiofrequency Ablation Combined With External Beam Radiation Therapy for Patients With Inoperable Non-Small Cell Lung Cancer. International Journal of Radiation Oncology*Biology*Physics. 111(1). 152–156. 6 indexed citations
6.
Lycan, Thomas, et al.. (2021). P48.01 Gemcitabine and Nivolumab for Subsequent Treatment of Metastatic Small Cell Lung Cancer. Journal of Thoracic Oncology. 16(3). S499–S499. 3 indexed citations
7.
Ahmed, Tamjeed, et al.. (2019). P2.04-93 Performance Status and Age as Predictors of Immunotherapy Outcomes in Advanced Non-Small Cell Lung Cancer. Journal of Thoracic Oncology. 14(10). S746–S747. 1 indexed citations
8.
Roberts, Nathan B., et al.. (2019). OA01.04 Safety and Efficacy of Flu Vaccination After Treatment with Immune Checkpoint Inhibitors: a Retrospective Review. Journal of Thoracic Oncology. 14(11). S1125–S1125. 3 indexed citations
9.
Stinchcombe, Thomas E., David Kozono, Joseph K. Salama, et al.. (2017). MA 17.07 Veliparib in Combination with Paclitaxel/Carboplatin (P/C)-Based Chemoradiotherapy (CRT) in Patients with Stage III NSCLC. Journal of Thoracic Oncology. 12(11). S1874–S1874. 1 indexed citations
10.
Kilburn, Jeremy M., John T. Lucas, M. Soike, et al.. (2016). Is a Clinical Target Volume (CTV) Necessary in the Treatment of Lung Cancer in the Modern Era Combining 4-D Imaging and Image-guided Radiotherapy (IGRT)?. Cureus. 8(1). e466–e466. 13 indexed citations
11.
Bellinger, Christina, et al.. (2016). Gene Expression Profiling of Non-small Cell Lung Cancer With Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration. CHEST Journal. 150(4). 702A–702A. 1 indexed citations
12.
Lewis, Jennifer A., W. Jeffrey Petty, Janet A. Tooze, et al.. (2015). Low-Dose CT Lung Cancer Screening Practices and Attitudes among Primary Care Providers at an Academic Medical Center. Cancer Epidemiology Biomarkers & Prevention. 24(4). 664–670. 127 indexed citations
13.
Petty, W. Jeffrey, et al.. (2011). High cyclin D3 expression confers erlotinib resistance in aerodigestive tract cancer. Lung Cancer. 74(3). 384–391. 12 indexed citations
14.
Stinchcombe, Thomas E., Mark A. Socinski, Dominic T. Moore, et al.. (2011). Phase I/II trial of bevacizumab (B) and erlotinib (E) with induction (IND) and concurrent (CON) carboplatin (Cb)/paclitaxel (P) and 74 Gy of thoracic conformal radiotherapy (TCRT) in stage III non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 29(15_suppl). 7016–7016. 7 indexed citations
15.
Weaver, Kathryn E., et al.. (2010). Effects of continued tobacco use during treatment of lung cancer. Expert Review of Anticancer Therapy. 10(10). 1569–1575. 23 indexed citations
16.
Petty, W. Jeffrey, Antonius A. Miller, Thomas P. McCoy, et al.. (2009). Phase I and Pharmacokinetic Study of Angiotensin-(1-7), an Endogenous Antiangiogenic Hormone. Clinical Cancer Research. 15(23). 7398–7404. 77 indexed citations
17.
Dragnev, Konstantin H., W. Jeffrey Petty, Sumit J. Shah, et al.. (2007). A Proof-of-Principle Clinical Trial of Bexarotene in Patients with Non–Small Cell Lung Cancer. Clinical Cancer Research. 13(6). 1794–1800. 63 indexed citations
18.
Petty, W. Jeffrey, Konstantin H. Dragnev, Vincent A. Memoli, et al.. (2005). PROOF-OF-PRINCIPLE CLINICAL TRIAL OF BEXAROTENE FOR THE TREATMENT OF NON-SMALL CELL LUNG CANCER. CHEST Journal. 128(4). 312S–312S. 1 indexed citations
19.
Pitha, Ian, W. Jeffrey Petty, Sutisak Kitareewan, & Ethan Dmitrovsky. (2003). Retinoid target genes in acute promyelocytic leukemia. Leukemia. 17(9). 1723–1730. 53 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Arta M. Monjazeb Breakdown of academic impact, for papers by Paul Cozzi Breakdown of academic impact, for papers by William Proctor Harris Breakdown of academic impact, for papers by Amanda J. Redig Breakdown of academic impact, for papers by Kostas Syrigos Breakdown of academic impact, for papers by Amit A. Lugade Breakdown of academic impact, for papers by Xiaodong Zhu Breakdown of academic impact, for papers by Adnan Ghafoor Breakdown of academic impact, for papers by Urban Emmenegger Breakdown of academic impact, for papers by Tokujiro Yano
Rankless by CCL
2026